WHO Validates First Test to Detect the Bundibugyo Ebola Virus

A green light granted in the middle of a health emergency

On July 2, 2026, the World Health Organization announced the addition of the very first molecular diagnostic test specifically designed to detect the Bundibugyo strain of the Ebola virus to its Emergency Use Listing. The test, manufactured by the Chinese company Shanghai ZJ Bio-Tech, works through real-time PCR and detects the virus's genetic material directly in blood samples, allowing rapid and precise confirmation of infection.

This approval comes as the outbreak declared on May 17, 2026, in the Democratic Republic of Congo and Uganda continues to spread, with several hundred confirmed and probable cases according to data compiled by the U.S. Centers for Disease Control and Prevention.

Existing tools that could not detect Bundibugyo

Unlike the Zaire strain, responsible for the majority of Ebola outbreaks in the DRC over recent decades, the Bundibugyo strain had only been identified in two previous episodes, in 2007 and 2012. That relative rarity meant the most widely used diagnostic tools in the field, such as the Xpert Ebola test commonly deployed during earlier interventions, simply were not built to recognize its specific genetic material.

According to the Africa CDC, the GeneXpert platform, which has become an almost standard tool in the response to Ebola outbreaks across the African continent, also fails to detect the Bundibugyo virus, which considerably complicated the first weeks of the health response in remote areas of eastern Congo.

Critical weeks without a reliable decentralized tool

During the early weeks of the outbreak, medical teams had to rely on generic pan-filovirus tests, such as the RealStar Filovirus Screen, available only in centralized reference laboratories rather than in the decentralized areas hit hardest. That logistical delay mechanically slowed the isolation of confirmed patients, a crucial factor in curbing the virus's spread within communities already weakened by a difficult humanitarian context.

An independent diagnostic monitoring report published in mid-June noted that, at that point, no rapid antigen-based screening test yet met the technical requirements set by the WHO for reliable use against this particular strain, forcing field teams to make do with imperfect tools.

A massive expansion of screening capacity

According to Clinical Trials Arena, the approval of this new test will allow, through collaboration between the WHO and the Africa CDC, laboratory screening capacity to expand to more than 2,000 tests per day, a substantial increase over the limited capacity of the centralized reference laboratories that had prevailed until now. This scale-up represents a major shift for a health response that had until now relied on scattered and insufficient diagnostic resources.

The WHO's Emergency Use Listing procedure, however, does not amount to a permanent approval: it authorizes temporary, regulated use of the test for the duration of the health emergency, while more complete validation data can be gathered under real clinical conditions.

Numbers that keep climbing despite the mobilization

The current outbreak was classified a Public Health Emergency of International Concern by the WHO as early as May 17, 2026, a designation that, according to the organization, still does not reach the threshold of a pandemic emergency. According to data reported by The Guardian shortly after that announcement, the outbreak had already caused more than 80 deaths and counted 246 suspected cases at the time of the initial declaration, a toll that continued to grow in the following weeks according to successive updates from health authorities.

Other independent epidemiological trackers were already citing, by mid-June, a total approaching 600 suspected cases and 139 deaths attributed to this specific strain, a fatality rate that underscores the particular severity of this viral family, even as the exact figures continue to shift as the epidemiological investigation advances.

Why the existing Ebola vaccine falls short here

Unlike the Zaire strain, for which the ERVEBO vaccine has been approved and widely deployed for several years, no approved vaccine currently exists specifically against the Bundibugyo virus. The WHO even explicitly recommended, on May 28, 2026, against using the rVSV-ZEBOV vaccine outside of rigorously controlled research settings for this particular outbreak, citing insufficient evidence of cross-protection between the two strains.

The most promising vaccine candidate, developed by the International AIDS Vaccine Initiative, would still need roughly seven to nine months before it could be submitted for clinical efficacy evaluation, a timeline that illustrates well why rapid diagnosis remains, for now, the most concrete tool available to field teams.

A priority combination of antibodies and antivirals

According to a report published in the journal Nature, an expert committee convened by the WHO recommended, as early as May 28, 2026, prioritizing clinical evaluation of three therapeutic candidates: the monoclonal antibodies MBP134 and maftivimab, along with the antiviral remdesivir, with particular attention to a possible combination therapy pairing a monoclonal antibody with that antiviral. Reuters also confirmed that a clinical trial testing these experimental treatments officially began in the DRC on July 2, 2026, the same day as the announcement of the new diagnostic test.

For prevention among people who have been in contact with confirmed cases, the oral antiviral obeldesivir has also been identified as a priority candidate, an approach that nonetheless depends heavily on the effectiveness of contact tracing on the ground, a major operational challenge in areas where the humanitarian crisis already complicates access to populations.

A coordinated effort across several global institutions

This approval would not have been possible without close collaboration between the WHO, the Africa CDC, the organization Unitaid, and technical partners such as FIND and PATH, who helped support the development of a specific validation framework for diagnostic tests targeting the Bundibugyo virus. This cooperation illustrates how an effective international health response rarely rests on a single institution acting alone.

Manufacturer Shanghai ZJ Bio-Tech is not the only player to have submitted a candidate: several other manufacturers, including Altona Diagnostics and Liferiver, have tests capable of detecting the Bundibugyo virus, even though not all of them can distinguish it from other ebolavirus species, an important technical nuance for laboratory teams on the ground.

What this approval enables, and what it still doesn't

Adding this test to the WHO's Emergency Use Listing represents a concrete and measurable step forward in the response to this outbreak, by speeding up case detection and unlocking far greater screening capacity than existed before. But this diagnostic advance replaces neither an approved vaccine nor a specific approved treatment, two elements that remain at the experimental stage for the Bundibugyo strain.

The response to this outbreak will therefore continue to rest, for now, on the same public health fundamentals that have always proven effective against Ebola: active surveillance, rapid case isolation, rigorous contact tracing, and intensive supportive care delivered by protected and trained medical teams.

Vigilance that must remain measured, without giving in to panic

The WHO continues to advise against any travel or trade restrictions on the DRC or Uganda based on currently available information, noting that such measures are generally driven by fear rather than solid scientific data. This new diagnostic test should be seen for what it is: a valuable additional tool, not a definitive solution to an outbreak that still demands a great deal of rigor and patience.

By Maxime Marquette, columnist

Editorial stance

I am not a journalist but a columnist and analyst. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. I claim analytical clarity, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

Method and sources

This text keeps the basic distinction between verified facts and interpretive analysis. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under Sources, never here.

Primary source families used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

Secondary source families: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under Sources.

Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a critical, contextual synthesis based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.